The bill, known as Senate Bill No. 109, mandates that health benefit plans in Oklahoma, including the Oklahoma Employees Insurance Plan, provide coverage for specific genetic testing and cancer imaging. It defines key terms such as "clinical utility," "evidence-based cancer imaging," and "genetic testing for an inherited mutation." The bill stipulates that coverage must be provided for clinical genetic testing for individuals with a personal or family history of cancer, as well as for evidence-based cancer imaging for those at increased risk of cancer, provided these tests are ordered by a healthcare provider and meet established clinical guidelines.

Additionally, the bill ensures that coverage for these services will not be subject to annual deductibles, copayments, or coinsurance limits. It also addresses the implications for health savings accounts, stating that the provisions will apply to qualified high deductible health plans after the minimum deductible is met, while still allowing for preventive care services to be covered regardless of deductible status. The act is set to take effect on November 1, 2025.